Clinical impact of vancomycin-resistant enterococci.
In humans, vancomycin-resistant enterococci (VRE) most commonly result in intestinal colonization, which does not result in symptoms, may persist for a long time and serves as a reservoir for transmission of VRE to other patients. Certain VRE-colonized patients are at risk of infection, including haematology and oncology patients, patients in intensive care units and recipients of solid (especially abdominal) organ transplants. Controlling the spread of VRE colonization and preventing colonized patients from becoming infected are important aims. Ramoplanin is a member of a new class of antimicrobial agents; it may have a role in preventing infection in patients colonized with VRE.
Patel
Robin
R
Division of Infectious Diseases, Department of Internal Medicine, Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Infectious Diseases Research Laboratory, Mayo Clinic, MN, USA. patel.robin@mayo.edu
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003428:Cross Infection / Q000517:prevention & control* / Q000635:transmission; D047630:Depsipeptides; D016983:Enterococcus / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D016908:Gram-Positive Bacterial Infections / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D017053:Infection Control; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D020713:Vancomycin Resistance / Q000235:genetics*
D000900:Anti-Bacterial Agents; D047630:Depsipeptides; D010456:Peptides, Cyclic; C041438:ramoplanin